Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 305

1.

The use of TNF-inhibitors in ankylosing spondylitis in Austria from 2007 to 2009 - a retrospective analysis.

Nell-Duxneuner V, Schroeder Y, Reichardt B, Bucsics A.

Int J Clin Pharmacol Ther. 2012 Dec;50(12):867-72. doi: 10.5414/CP201707.

PMID:
23036238
2.

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.

Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.

J Manag Care Pharm. 2013 Oct;19(8):621-30.

3.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

4.

Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.

Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M.

J Med Econ. 2012;15(6):1054-63. doi: 10.3111/13696998.2012.692341. Epub 2012 Jun 11.

PMID:
22563743
5.

Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.

Bonafede MM, Gandra SR, Watson C, Princic N, Fox KM.

Adv Ther. 2012 Mar;29(3):234-48. doi: 10.1007/s12325-012-0007-y. Epub 2012 Mar 9.

PMID:
22411424
6.

Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.

Bonafede M, Fox KM, Watson C, Princic N, Gandra SR.

Adv Ther. 2012 Aug;29(8):664-74. doi: 10.1007/s12325-012-0037-5. Epub 2012 Aug 8.

PMID:
22886712
7.

Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States.

Schabert VF, Watson C, Gandra SR, Goodman S, Fox KM, Harrison DJ.

J Med Econ. 2012;15(2):264-75. doi: 10.3111/13696998.2011.644645. Epub 2011 Dec 8.

PMID:
22115327
8.

Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database.

Wendling D, Joshi A, Reilly P, Jalundhwala YJ, Mittal M, Bao Y.

Curr Med Res Opin. 2014 Dec;30(12):2515-21. doi: 10.1185/03007995.2014.969368. Epub 2014 Oct 8.

PMID:
25252590
9.

Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.

Carter CT, Changolkar AK, Scott McKenzie R.

J Med Econ. 2012;15(2):332-9. doi: 10.3111/13696998.2011.649325. Epub 2012 Jan 6.

PMID:
22168788
10.

Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.

Ollendorf DA, Klingman D, Hazard E, Ray S.

Clin Ther. 2009 Apr;31(4):825-35. doi: 10.1016/j.clinthera.2009.04.002.

PMID:
19446156
11.

Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.

Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.

J Rheumatol. 2011 Jul;38(7):1273-81. doi: 10.3899/jrheum.101142. Epub 2011 May 15.

PMID:
21572150
12.

Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents.

Braun J, Baraliakos X, Listing J, Davis J, van der Heijde D, Haibel H, Rudwaleit M, Sieper J.

Arthritis Rheum. 2007 May 15;57(4):639-47. Review.

13.

Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period.

Conti F, Ceccarelli F, Marocchi E, Magrini L, Spinelli FR, Spadaro A, Scrivo R, Valesini G.

Ann Rheum Dis. 2007 Oct;66(10):1393-7. Epub 2007 Jul 5.

14.

Comparison of drug survival rates for adalimumab, etanercept and infliximab in patients with psoriasis vulgaris.

Gniadecki R, Kragballe K, Dam TN, Skov L.

Br J Dermatol. 2011 May;164(5):1091-6. doi: 10.1111/j.1365-2133.2011.10213.x. Epub 2011 Apr 11.

PMID:
21219290
15.

Efficiency of adalimumab, etanercept and infliximab in ankylosing spondylitis in clinical practice.

Escudero-Vilaplana V, Ramírez-Herráiz E, Alañón-Plaza E, Trovato-López N, García-Vicuña R, Carreño-Pérez L, Morell-Baladrón A, Sanjurjo-Sáez M.

Int J Clin Pharm. 2015 Oct;37(5):808-14. doi: 10.1007/s11096-015-0124-1. Epub 2015 Apr 25.

PMID:
25910480
16.

Annual acquisition and administration cost of biologic response modifiers per patient with rheumatoid arthritis, psoriasis, psoriatic arthritis, or ankylosing spondylitis.

Bonafede M, Joseph GJ, Princic N, Harrison DJ.

J Med Econ. 2013 Sep;16(9):1120-8. doi: 10.3111/13696998.2013.820192. Epub 2013 Jul 18.

PMID:
23808901
17.

Do tumor necrosis factor inhibitors cause uveitis? A registry-based study.

Lim LL, Fraunfelder FW, Rosenbaum JT.

Arthritis Rheum. 2007 Oct;56(10):3248-52.

18.

Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study.

Arends S, Brouwer E, van der Veer E, Groen H, Leijsma MK, Houtman PM, Th A Jansen TL, Kallenberg CG, Spoorenberg A.

Arthritis Res Ther. 2011 Jun 20;13(3):R94. doi: 10.1186/ar3369.

19.

Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period.

Gomez-Reino JJ, Carmona L; BIOBADASER Group.

Arthritis Res Ther. 2006;8(1):R29. Epub 2006 Jan 6.

20.

Incidence of tuberculosis among korean patients with ankylosing spondylitis who are taking tumor necrosis factor blockers.

Kim EM, Uhm WS, Bae SC, Yoo DH, Kim TH.

J Rheumatol. 2011 Oct;38(10):2218-23. doi: 10.3899/jrheum.110373. Epub 2011 Aug 15.

PMID:
21844149

Supplemental Content

Support Center